M&A / Deals Ambrosia adds a megaround for obesity drugs BioPharma DiveThe $100 million Series B round will be used to bring the biotech s oral GLP-1 into early human testing.M&A / DealsMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioPharma Dive The $100 million Series B round will be used to bring the biotech s oral GLP-1 into early human testing. M&A / DealsMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA approves new high dose Spinraza regimen for SMANext: FDA Approves First New Molecular Entity Under National Priority Voucher Program Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
